leadership, adopting innovative and sustainable approaches, and scaling up national malaria programmes to deliver lifesaving tools to those at highest risk.”
Dangote then acknowledged the positive efforts of the Nigerian National Agency for Food and Drug Administration and Control (NAFDAC) as the second national drug regulator to approve the use of the R21 vaccine, saying the fight against the malaria scourge has been buoyed by the introduction of the new malaria vaccine -R21/Matrix-M, which was developed by the University of Oxford and will be manufactured by the Serum Institute of India.
“As we look forward to its rollout soon. All efforts must be made to sustain the adequate sourcing and application of this innovative vaccine in the fight against malaria; akin to the noble efforts made to ensure the eradication of polio in Nigeria and Africa”, he concluded.
